The estimated Net Worth of Philip P. Breitfeld is at least $465 Thousand dollars as of 12 October 2022. Philip Breitfeld owns over 8,333 units of Champions Oncology Inc stock worth over $74,074 and over the last 8 years he sold CSBR stock worth over $356,878. In addition, he makes $34,182 as Independent Director at Champions Oncology Inc.
Sign up
Philip Breitfeld CSBR stock SEC Form 4 insiders trading
Philip has made over 3 trades of the Champions Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,333 units of CSBR stock worth $26,749 on 12 October 2022.
The largest trade he's ever made was selling 31,443 units of Champions Oncology Inc stock on 16 December 2020 worth over $356,878. On average, Philip trades about 3,662 units every 55 days since 2016. As of 12 October 2022 he still owns at least 18,200 units of Champions Oncology Inc stock.
You can see the complete history of Philip Breitfeld stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Philip Breitfeld biography
Dr. Philip Breitfeld M.D. serves as Independent Director of the Company. Dr. Breitfeld was most recently Global Vice President at Quintiles, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at Quintiles where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior clinical development positions at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst, where he led oncology development and was Associate Chief Medical Officer. He has approximately 50 publications in the literature dealing with basic cell and molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton.
What is the salary of Philip Breitfeld?
As the Independent Director of Champions Oncology Inc, the total compensation of Philip Breitfeld at Champions Oncology Inc is $34,182. There are 8 executives at Champions Oncology Inc getting paid more, with Ronnie Morris having the highest compensation of $1,343,650.
How old is Philip Breitfeld?
Philip Breitfeld is 67, he's been the Independent Director of Champions Oncology Inc since 2016. There are 1 older and 8 younger executives at Champions Oncology Inc. The oldest executive at Champions Oncology Inc is Abba Poliakoff, 68, who is the Independent Director.
What's Philip Breitfeld's mailing address?
Philip's mailing address filed with the SEC is ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK, NJ, 07601.
Insiders trading at Champions Oncology Inc
Over the last 21 years, insiders at Champions Oncology Inc have traded over $9,072,751 worth of Champions Oncology Inc stock and bought 42,104,566 units worth $13,657,266 . The most active insiders traders include Ventures Ix, L.P.Battery In..., Michael Maurice Brown, and Sports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of $2,196,294. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth $6,500.
What does Champions Oncology Inc do?
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
What does Champions Oncology Inc's logo look like?
Complete history of Philip Breitfeld stock trades at Champions Oncology Inc
Champions Oncology Inc executives and stock owners
Champions Oncology Inc executives and other stock owners filed with the SEC include:
-
Ronnie Morris,
Chief Executive Officer, Director -
Dr. Ronnie Morris M.D.,
Pres, CEO & Director -
David Miller,
Chief Financial Officer -
David Barry Miller M.B.A.,
Chief Financial Officer -
Joel Ackerman,
Chairman of the Board -
Scott Tobin,
Independent Director -
Abba Poliakoff,
Independent Director -
Daniel Mendelson,
Independent Director -
David Sidransky,
Lead Independent Director -
Philip Breitfeld,
Independent Director -
David DeOrnellis BS, CMAR, CPIA, RLATG,
Exec. VP of Global Laboratory Operations -
Dr. Maria Mancini Ph.D.,
Chief of Scientific Operations -
Dr. Michael Ritchie M.B.A., Ph.D.,
Chief Commercial Officer -
Dr. Karin Abarca Heidemann,
VP of Scientific Operations -
Ventures Ix, L.P.Battery In...,
-
Michael Maurice Feldman Jes...,
-
Ventures Ix, L.P.Battery In...,
-
Arthur G Iii Epker,
Director -
Michael Maurice Brown,
10% owner -
James Martell,
Chief Accounting Officer -
Ana Stancic,
Director -
Douglas D Burkett,
President -
Mark Schonau,
Chief Financial Officer -
Durwood Settles,
Director -
Sports Inc Champions,
Chairman, President -
Enterprise Associates 14, L...,
-
Brady Davis,
President